Resources
-
Navigating Critical Reagent Challenges in Cell-Based Potency Assays: Case Studies on Variability and Solutions
Speaker Presentation: Bioassays 2026
Patel Bhoomi Jani, BioAgilytix Labs, LLC, 2026 -
Challenges and Strategies for Potency Assay Development in High-Valency Vaccines
Speaker Presentation: Bioassays 2026
Grozdanovic Milica, Merck & Co., Inc., 2026 -
Advancing Drug Development: Utilizing T-cell Activation Reporter Gene Assays for Potency Monitoring from the Pre-Clinical to the Commercial Stages
Speaker Presentation: Bioassays 2026
Feng Felix, AstraZeneca, 2026 -
Nutty About Potency: Bolting Down a Robust Late-Stage Relative Potency Assay
Speaker Presentation: Bioassays 2026
Farmer Erika, AstraZeneca, 2026 -
Potency Assay Generated Data - Is It a Minefield or a Knowledge Bank and Are They Useable
Speaker Presentation: Bioassays 2026
Amstrup Jan, Novo Nordisk, 2026 -
Bioassays 2026 Scientific Program
Scientific Program: Bioassays 2026
-
Bioassays 2026 Summary Infographic
Summary Infographic: Bioassays 2026
-
Development of New Reference Material for Biopharmaceutical Advancement
Speaker Presentation: Consultants' Network March 2026
Telikepalli Srivalli, National Institute of Standards and Technology (NIST), 2026 -
Visible Particle Control in Biologics and ATMPs: Bridging Regulatory Requirements with Practical Qualification Standards
Speaker Presentation: Consultants' Network March 2026
Koulov Atanas, Clear Solutions Laboratories, 2026 -
Workshop Session 3 - Troubleshooting Technology Transfers Together – aka Two Heads are Better than One
Speaker Presentation: WCBP 2026
Workshop Session 3 - Troubleshooting Technology Transfers Together – aka Two Heads are Better than One -
Workshop Session 3 - Qualification of Potency Reference Standards, Considerations for Reference Standards for Multispecifics, Multiple Antigens, or Multiple Mechanisms of Action
Speaker Presentation: WCBP 2026
Workshop Session 3 - Qualification of Potency Reference Standards, Considerations for Reference Standards for Multispecifics, Multiple Antigens, or Multiple Mechanisms of Action -
Workshop Session 3 - In-Use Compatibility and Stability Studies
Speaker Presentation: WCBP 2026
Workshop Session 3 - In-Use Compatibility and Stability Studies -
Workshop Session 3 - Comprehensive Approach for Technology Transfers: To PACMP or Not to PACMP?
Speaker Presentation: WCBP 2026
Workshop Session 3 - Comprehensive Approach for Technology Transfers: To PACMP or Not to PACMP? -
Workshop Session 2 - Opportunities and Challenges of Expanding US-based Manufacturing
Speaker Presentation: WCBP 2026
Workshop Session 2 - Opportunities and Challenges of Expanding US-based Manufacturing -
Workshop Session 2 - Latest Learning From AI as a Tool, Both From the Lens of Industry and Agency
Speaker Presentation: WCBP 2026
Workshop Session 2 - Latest Learning From AI as a Tool, Both From the Lens of Industry and Agency -
Workshop Session 2 - Beyond the Molecule: Navigating Comparability Across Drug Delivery Presentations
Speaker Presentation: WCBP 2026
Workshop Session 2 - Beyond the Molecule: Navigating Comparability Across Drug Delivery Presentations -
Workshop Session 1 - Shaken, Stirred, and Stable? Tales from a CMC Multivalent Cocktail Party
Speaker Presentation: WCBP 2026
Workshop Session 1 - Shaken, Stirred, and Stable? Tales from a CMC Multivalent Cocktail Party -
Workshop Session 1 - Partnering With CMOs and CTOs - Opportunities and Challenges for Effective Collaboration and Lifecycle Success
Speaker Presentation: WCBP 2026
Workshop Session 1 - Partnering With CMOs and CTOs - Opportunities and Challenges for Effective Collaboration and Lifecycle Success -
Workshop Session 1 - From Batch Data to Patient Needs: Rethinking Specifications in ICH Q6
Speaker Presentation: WCBP 2026
Workshop Session 1 - From Batch Data to Patient Needs: Rethinking Specifications in ICH Q6 -
Technical Seminar Presented by USP, 2026
Speaker Presentation: WCBP 2026
Technical Seminar Presented by USP, 2026